The WHO/Europe Access to Novel Medicines Platform (NMP) working group 3 meeting aims to develop principles that recognize the need for sustainable health systems and pharmaceutical industries, and enable risk-sharing and good governance of markets, including addressing market failures and unmet needs. These principles apply to, among others, payment, pricing, health technology assessment and reimbursement policies. Chaired by Meindert Boysen, Head of International Affairs at the National Institute for Health and Care Excellence, United Kingdom, the working group is exploring what financial arrangements can be put in place to manage uncertainties around managed entry agreements, what cross-border agreements can be developed to support buyer coalitions in the WHO European Region, and what financial principles could be utilized to ensure sustainability in lower-resourced settings.
The NMP comprises 4 working groups – following the themes of transparency, solidarity, sustainability and antimicrobial resistance – working to identify concrete actions to improve affordable and equitable access to effective, novel, high-cost medicines in the European Region. WHO/Europe acts as the neutral convenor of the NMP ensuring a multistakeholder perspective and a “voice for all” to enrich proposals.
Participation in the working groups is through nominations made by the registered NMP stakeholders, including Member States, non-State actors and other partner organizations.
For more information about the meeting, please reach out to the NMP secretariat at euro-nmp@who.int